Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma

• Main Authors: Zheng Feng (Author), Di Shao (Author), Yuhang Cai (Author), Rui Bi (Author), Xingzhu Ju (Author), Dongju Chen (Author), Chengcheng Song (Author), Xiaojun Chen (Author), Jin Li (Author), Na An (Author), Yunjin Li (Author), Qing Zhou (Author), Zhihui Xiu (Author), Shida Zhu (Author), Xiaohua Wu (Author), Hao Wen (Author)
• Format: Book
• Published: BMC, 2023-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Homologous Recombination Deficiency (HRD) is a predictive biomarker for ovarian cancer treated with PARP inhibitors or for breast cancer treated with first-line platinum-based chemotherapy. However, limited research is documented on platinum-based treatment prediction with HRD as...